Search results
Showing 7546 to 7560 of 8215 results
QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)
This advice has been updated and replaced by NICE healthtech guidance 729.
Point-of-care creatinine tests before contrast-enhanced imaging (MIB136)
This advice has been replaced by NICE HealthTech guidance 530.
We have moved Diagnostics guidance 32 to become HealthTech guidance 467. This is to better reflect the NICE HealthTech programme, which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Rapid tests for group A streptococcal infections in people with a sore throat (DG38)
We have moved Diagnostics guidance 38 to become HealthTech guidance 531. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 61 to become HealthTech guidance 730. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]
Discontinued Reference number: GID-TA10306
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
Discontinued Reference number: GID-TA10334
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued Reference number: GID-TA10315
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]
Discontinued Reference number: GID-TA10327
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]
Discontinued Reference number: GID-TA10309
Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]
Discontinued Reference number: GID-TA10330
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued Reference number: GID-TA10295
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]
Discontinued Reference number: GID-TA10322
Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353
Discontinued Reference number: GID-TA10320
Discontinued Reference number: GID-TA10271